Comparing Effectiveness of Aripiprazole Augmentation, rTMS Augmentation, and Switching to Venlafaxine XR in Treatment Resistant Depression (ASCERTAIN-TRD)

  • STATUS
    Recruiting
Send
Updated on 19 February 2024

Summary

This is a multi-site, randomized, open-label, to compare the efficacy of aripiprazole augmentation, rTMS augmentation, and switching to venlafaxine XR as treatments for treatment-resistant depression.

Description

Subjects will be randomized to one of three treatment arms: a) aripiprazole added to the current antidepressant, b) rTMS added to the current antidepressant, and c) switching to venlafaxine XR. All subjects will be followed for 8 weeks to examine the efficacy of the study treatments.

FAQ

You might be eligible to participate if you are: - 18-80 years old; - diagnosed with Major Depressive Disorder; - currently on an antidepressant medication but haven’t experienced at least 50 % improvement in your symptoms; - tried at least 1 other antidepressant medication but did not experience at least 50 % improvement in your symptoms; - able to provide written consent to participate in the study. The study doctor will discuss additional requirements for being in the study with you.

Details
Condition Depression, Major depression, Depression, depression
Age 18years - 80years
Clinical Study IdentifierTX4803
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.